Clinical Trial Update: Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating prophylaxis and efficacy, safety, and pharmacokinetics of a B-domain deleted recombinant Factor VIII for Hemophilia A; study com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• B-domain deleted recombinant Factor VIII (recombinant Factor VIII (B-domain deleted))

Snippet

Sponsor: Pfizer | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2019-01-11